Elevance Health, Inc. (ELV)

Elevance Health's stock price has experienced a significant decline in the past six months. Recent events impacting the stock include the Q2 2025 Earnings Report, which led to a negative market reaction due to missed EPS expectations and a lowered annual profit forecast. Analyst downgrades and price target revisions from Deutsche Bank, TD Cowen, and Argus also impacted the stock. Multiple law firms announced class action lawsuits against Elevance Health, Inc. on behalf of investors, alleging securities fraud.

Elevance Health's products and services exhibit some demand seasonality, particularly within its government-backed plans. Medicare Advantage cost trends are in line with expectations, with Part D seasonality progressing as anticipated. The company has noted lower effectuation rates in its Affordable Care Act (ACA) business, which can also contribute to seasonal variations in membership. Elevance Health is actively managing these evolving market dynamics by focusing on managing costs and repricing products.

Elevance Health, Inc. (ELV) is an American for-profit health insurance provider in the Healthcare sector, focusing on improving health by simplifying healthcare through an integrated whole-health approach. It offers health plans and services across four segments: Health Benefits, CarelonRx, Carelon Services, and Specialty Insurance Products. As of December 2024, Elevance Health provided medical benefits to approximately 46 million members, integrating insurance, pharmacy, and care delivery services.

Elevance Health operates as a Blue Cross Blue Shield Association licensee in 14 states, holding a number-one or number-two membership position in all of them, including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, and Wisconsin. Through affiliated companies and acquisitions, its reach extends beyond these states, particularly through government-sponsored programs like Medicaid and Medicare Advantage plans, and it also serves members in Puerto Rico. Overall, Elevance Health touches the lives of approximately 115.2 million individuals through its affiliated companies and diverse services.

Elevance Health's brand reputation has been influenced by strategic initiatives and challenges. The company rebranded from Anthem, Inc. to Elevance Health, Inc., signaling a strategic realignment. Historically, the company has faced scrutiny and legal challenges, including data breaches and shareholder lawsuits alleging securities fraud. On a positive note, Elevance Health has been recognized for its workplace environment and announced promising results from a digital asthma self-management program.

Elevance Health's ownership is primarily composed of institutional investors, with a smaller percentage held by insiders and retail investors. Approximately 88.92% of the company's stock is held by institutional shareholders, with Vanguard Group Inc. being the largest. Retail investors hold approximately 8.42% of the stock. Insiders own about 2.66% of the company's stock, with net selling activity in the past year.